Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [

Olga Bragina, Liubov Tashireva, Dmitriy Loos, Vladimir Chernov, Sophia Hober, Vladimir Tolmachev

Open access · goldAbstract read

In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

1.1field-weighted citation impact, top 20% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Olga BraginaDepartment of Nuclear Therapy and Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, Russia.

Liubov TashirevaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634009, Russia.ORCID 0000-0003-2061-8417

Dmitriy LoosDepartment of General and Molecular Pathology, Tomsk National Research Medical Center, Tomsk 634014, Russia.

Vladimir ChernovDepartment of Nuclear Therapy and Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, Russia.

Sophia HoberDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 100 44 Stockholm, Sweden.ORCID 0000-0003-0605-8417

Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 81 Uppsala, Sweden.ORCID 0000-0002-6122-1734

Russian Academy of Sciences · RUKTH Royal Institute of Technology · SETomsk National Research Medical Center · RUUppsala University · SE

Funding

Swedish Cancer Society 2101485Swedish Research Council 2023-02158

6 · The paper itself

Abstract

Due to its small size and high affinity binding, the engineered scaffold protein ADAPT6 is a promising targeting probe for radionuclide imaging of human epidermal growth factor receptor type 2 (HER2). In a Phase I clinical trial, [

Indexed as

ADAPT6clinical studyHER2radionuclide molecular imagingscaffold proteintechnetium-99m

Identifiers

PMID38675107

DOI10.3390/pharmaceutics16040445

PMCPMC11053875

OpenAlexW4393149437

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.